Literature DB >> 16702898

Early predictors of substantial weight gain in bipolar patients treated with olanzapine.

Ilya Lipkovich1, Leslie Citrome, Roy Perlis, Walter Deberdt, John P Houston, Jonna Ahl, Thomas Hardy.   

Abstract

To determine predictors of substantial weight gain (SWG) during treatment of bipolar disorder with olanzapine, data were pooled from 4 long-term randomized, multicenter studies in patients with bipolar mania or mixed mania (N = 948 at initiation of olanzapine). SWG was defined as gaining 5 kg or 7% of initial weight in 30 +/- 2 weeks. Logistic regression estimated odds ratios associated with early weight gain and baseline risk factors for predicting SWG. A classification system to identify patients at risk for SWG was constructed by recursive data partitioning. Baseline characteristics significantly associated with SWG included younger age, nonwhite ethnicity, lower body mass index (BMI), nonrapid cycling, and psychotic features. Weight gain of 2 or more kg in the first 3 weeks of therapy predicted SWG by 30 weeks (sensitivity = 57%; specificity = 71%). A classification system with thresholds for early weight gain, baseline BMI, and ethnicity further improved SWG predictability (sensitivity = 79%; specificity = 70%). In conclusion, patients with bipolar disorder who gained 2 to 3 kg during the first 3 weeks of treatment with olanzapine, SWG was predicted after 30 weeks of treatment. Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702898     DOI: 10.1097/01.jcp.0000219916.88810.1c

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  14 in total

Review 1.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder.

Authors:  Jennifer E Wildes; Marsha D Marcus; Andrea Fagiolini
Journal:  Psychiatry Res       Date:  2008-09-07       Impact factor: 3.222

Review 3.  Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

Authors:  Karen L Teff; Sangwon F Kim
Journal:  Physiol Behav       Date:  2011-06-12

Review 4.  Obesity in bipolar disorder: an overview.

Authors:  Susan L McElroy; Paul E Keck
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

5.  A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Authors:  Barnett S Meyers; Alastair J Flint; Anthony J Rothschild; Benoit H Mulsant; Ellen M Whyte; Catherine Peasley-Miklus; Eros Papademetriou; Andrew C Leon; Moonseong Heo
Journal:  Arch Gen Psychiatry       Date:  2009-08

6.  Can body mass index help predict outcome in patients with bipolar disorder?

Authors:  Cynthia Calkin; Caroline van de Velde; Martina Růzicková; Claire Slaney; Julie Garnham; Tomas Hajek; Claire O'Donovan; Martin Alda
Journal:  Bipolar Disord       Date:  2009-09       Impact factor: 6.744

7.  A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.

Authors:  Kristina M Deligiannidis; Anthony J Rothschild; Bruce A Barton; Aimee R Kroll-Desrosiers; Barnett S Meyers; Alastair J Flint; Ellen M Whyte; Benoit H Mulsant
Journal:  J Clin Psychiatry       Date:  2013-10       Impact factor: 4.384

8.  Correlates of weight gain during long-term risperidone treatment in children and adolescents.

Authors:  Chadi Albert Calarge; Ginger Nicol; Diqiong Xie; Bridget Zimmerman
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2012-05-29       Impact factor: 3.033

9.  Review of olanzapine in the management of bipolar disorders.

Authors:  Meera Narasimhan; Travis O Bruce; Prakash Masand
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

10.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Authors:  Virginia L Stauffer; Ilya Lipkovich; Vicki Poole Hoffmann; Alexandra N Heinloth; H Scott McGregor; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-03-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.